3,773 reports of this reaction
3.8% of all EMPAGLIFLOZIN reports
#1 most reported adverse reaction
DIABETIC KETOACIDOSIS is the #1 most commonly reported adverse reaction for EMPAGLIFLOZIN, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 3,773 FDA adverse event reports linking EMPAGLIFLOZIN to DIABETIC KETOACIDOSIS. This represents approximately 3.8% of all 100,203 adverse event reports for this drug.
Patients taking EMPAGLIFLOZIN who experience diabetic ketoacidosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIABETIC KETOACIDOSIS is moderately reported among EMPAGLIFLOZIN users, representing a notable but not dominant share of adverse events.
In addition to diabetic ketoacidosis, the following adverse reactions have been reported for EMPAGLIFLOZIN:
The following drugs have also been linked to diabetic ketoacidosis in FDA adverse event reports:
DIABETIC KETOACIDOSIS has been reported as an adverse event in 3,773 FDA reports for EMPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIABETIC KETOACIDOSIS accounts for approximately 3.8% of all adverse event reports for EMPAGLIFLOZIN, making it one of the most commonly reported side effect.
If you experience diabetic ketoacidosis while taking EMPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.